Literature DB >> 30523328

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.

Guy Ledergor1,2, Assaf Weiner1, Mor Zada1, Shuang-Yin Wang1, Yael C Cohen3,4, Moshe E Gatt5,6, Nimrod Snir4,7, Hila Magen4,8, Maya Koren-Michowitz4,9, Katrin Herzog-Tzarfati4,9, Hadas Keren-Shaul1,10, Chamutal Bornstein1, Ron Rotkopf10, Ido Yofe1, Eyal David1, Venkata Yellapantula11,12, Sigalit Kay3, Moshe Salai4,7, Dina Ben Yehuda5,6, Arnon Nagler4,8, Lev Shvidel6,13, Avi Orr-Urtreger4,14, Keren Bahar Halpern15, Shalev Itzkovitz15, Ola Landgren16, Jesus San-Miguel17, Bruno Paiva17, Jonathan J Keats18, Elli Papaemmanuil12, Irit Avivi3,4, Gabriel I Barbash19, Amos Tanay20,21, Ido Amit22.   

Abstract

Multiple myeloma, a plasma cell malignancy, is the second most common blood cancer. Despite extensive research, disease heterogeneity is poorly characterized, hampering efforts for early diagnosis and improved treatments. Here, we apply single cell RNA sequencing to study the heterogeneity of 40 individuals along the multiple myeloma progression spectrum, including 11 healthy controls, demonstrating high interindividual variability that can be explained by expression of known multiple myeloma drivers and additional putative factors. We identify extensive subclonal structures for 10 of 29 individuals with multiple myeloma. In asymptomatic individuals with early disease and in those with minimal residual disease post-treatment, we detect rare tumor plasma cells with molecular characteristics similar to those of active myeloma, with possible implications for personalized therapies. Single cell analysis of rare circulating tumor cells allows for accurate liquid biopsy and detection of malignant plasma cells, which reflect bone marrow disease. Our work establishes single cell RNA sequencing for dissecting blood malignancies and devising detailed molecular characterization of tumor cells in symptomatic and asymptomatic patients.

Entities:  

Mesh:

Year:  2018        PMID: 30523328     DOI: 10.1038/s41591-018-0269-2

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  80 in total

Review 1.  Revolutionizing immunology with single-cell RNA sequencing.

Authors:  Haide Chen; Fang Ye; Guoji Guo
Journal:  Cell Mol Immunol       Date:  2019-02-22       Impact factor: 11.530

2.  Clonal evolution in myeloma: a narrow road to remission.

Authors:  Cornelius C Miething
Journal:  Haematologica       Date:  2019-07       Impact factor: 9.941

3.  Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.

Authors:  Yujia Wang; Lushuang Xu; Yang Liu; Yuzhe Hu; Qiang Shi; Lixue Jin; Lijun Yang; Pingzhang Wang; Kunshan Zhang; Xiaojun Huang; Qing Ge; Jin Lu
Journal:  Int J Hematol       Date:  2020-10-10       Impact factor: 2.490

4.  DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.

Authors:  Scott R Goldsmith; Mark A Fiala; Brandon Wang; Mark A Schroeder; Tanya M Wildes; Armin Ghobadi; Keith Stockerl-Goldstein; Ravi Vij
Journal:  Ann Hematol       Date:  2020-03-04       Impact factor: 3.673

Review 5.  Molecular basis of clonal evolution in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2020-02-06       Impact factor: 2.490

6.  Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis.

Authors:  Yuli Guzman-Prado; Jennifer Ben Shimol; Ondrej Samson
Journal:  Cancer Immunol Immunother       Date:  2020-07-09       Impact factor: 6.968

Review 7.  Programming Isotype-Specific Plasma Cell Function.

Authors:  Brett W Higgins; Louise J McHeyzer-Williams; Michael G McHeyzer-Williams
Journal:  Trends Immunol       Date:  2019-03-04       Impact factor: 16.687

8.  Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.

Authors:  Bachisio Ziccheddu; Giulia Biancon; Filippo Bagnoli; Chiara De Philippis; Francesco Maura; Even H Rustad; Matteo Dugo; Andrea Devecchi; Loris De Cecco; Marialuisa Sensi; Carolina Terragna; Marina Martello; Tina Bagratuni; Efstathios Kastritis; Meletios A Dimopoulos; Michele Cavo; Cristiana Carniti; Vittorio Montefusco; Paolo Corradini; Niccolo Bolli
Journal:  Blood Adv       Date:  2020-03-10

9.  A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.

Authors:  Stefania Oliva; Lorenzo De Paoli; Marina Ruggeri; Simona Caltagirone; Rossella Troia; Daniela Oddolo; Mattia D'Agostino; Milena Gilestro; Roberto Mina; Elona Saraci; Gloria Margiotta Casaluci; Elisa Genuardi; Sara Bringhen; Mario Boccadoro; Paola Omedé
Journal:  Ann Hematol       Date:  2021-01-03       Impact factor: 3.673

Review 10.  Advancing Cancer Research and Medicine with Single-Cell Genomics.

Authors:  Bora Lim; Yiyun Lin; Nicholas Navin
Journal:  Cancer Cell       Date:  2020-04-13       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.